OA11044A - Process for substituted pyridines - Google Patents

Process for substituted pyridines Download PDF

Info

Publication number: OA11044A
Authority: OA; OAPI
Prior art keywords: alkyl; compound; crc6; independently; formula
Prior art date: 1996-11-14

Application number

OA9900096A

Other languages

English (en)

Inventor

Keith Michael De Vries

Robert Lee Dow

Stephen Wayne Wright

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-14

Filing date

1999-05-07

Publication date

2002-02-20

1999-05-07 Application filed by Pfizer filed Critical Pfizer

2002-02-20 Publication of OA11044A publication Critical patent/OA11044A/en

Links

238000000034 method Methods 0.000 title claims abstract description 54
230000008569 process Effects 0.000 title claims abstract description 46
150000003222 pyridines Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 226
-1 nitro, amino Chemical group 0.000 claims abstract description 81
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 80
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 60
125000001153 fluoro group Chemical group F* 0.000 claims abstract description 28
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 4
125000000217 alkyl group Chemical group 0.000 claims description 211
229910052739 hydrogen Inorganic materials 0.000 claims description 108
125000005843 halogen group Chemical group 0.000 claims description 103
239000001257 hydrogen Substances 0.000 claims description 89
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 66
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 65
125000003545 alkoxy group Chemical group 0.000 claims description 57
238000006243 chemical reaction Methods 0.000 claims description 56
229910052760 oxygen Inorganic materials 0.000 claims description 55
229910052717 sulfur Chemical group 0.000 claims description 52
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 46
239000001301 oxygen Substances 0.000 claims description 46
125000004093 cyano group Chemical group *C#N 0.000 claims description 45
229910052757 nitrogen Inorganic materials 0.000 claims description 45
125000000623 heterocyclic group Chemical group 0.000 claims description 44
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 43
239000011593 sulfur Chemical group 0.000 claims description 43
239000000203 mixture Substances 0.000 claims description 39
125000004432 carbon atom Chemical group C* 0.000 claims description 38
125000001424 substituent group Chemical group 0.000 claims description 27
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 26
125000001309 chloro group Chemical group Cl* 0.000 claims description 26
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 26
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 25
239000012442 inert solvent Substances 0.000 claims description 23
125000004433 nitrogen atom Chemical group N* 0.000 claims description 23
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 22
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 claims description 22
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 20
125000004429 atom Chemical group 0.000 claims description 20
238000004519 manufacturing process Methods 0.000 claims description 19
239000002904 solvent Substances 0.000 claims description 19
229910052799 carbon Inorganic materials 0.000 claims description 18
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 15
125000006242 amine protecting group Chemical group 0.000 claims description 14
239000003446 ligand Substances 0.000 claims description 14
229910052762 osmium Inorganic materials 0.000 claims description 14
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
239000003054 catalyst Substances 0.000 claims description 12
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
230000000269 nucleophilic effect Effects 0.000 claims description 10
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
150000002431 hydrogen Chemical group 0.000 claims description 9
230000003287 optical effect Effects 0.000 claims description 9
239000007800 oxidant agent Substances 0.000 claims description 9
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
239000011260 aqueous acid Substances 0.000 claims description 8
125000004414 alkyl thio group Chemical group 0.000 claims description 7
150000001412 amines Chemical class 0.000 claims description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
125000003282 alkyl amino group Chemical group 0.000 claims description 6
YUCBLVFHJWOYDN-HVLQGHBFSA-N 1,4-bis[(s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@H](OC=3C4=CC=CC=C4C(O[C@H]([C@@H]4N5CC[C@H]([C@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-HVLQGHBFSA-N 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
239000012320 chlorinating reagent Substances 0.000 claims description 5
ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 claims description 5
125000002346 iodo group Chemical group I* 0.000 claims description 5
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
YUCBLVFHJWOYDN-PPIALRKJSA-N 4-[(r)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]-1-[(r)-[(2r,4r,5s)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@@H](OC=3C4=CC=CC=C4C(O[C@@H]([C@@H]4N5CC[C@@H]([C@@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-PPIALRKJSA-N 0.000 claims description 4
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 4
125000001246 bromo group Chemical group Br* 0.000 claims description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 3
150000008065 acid anhydrides Chemical class 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
229910052740 iodine Inorganic materials 0.000 claims description 3
125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
229910052744 lithium Inorganic materials 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 9
101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 claims 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
125000005948 methanesulfonyloxy group Chemical group 0.000 claims 1
125000004076 pyridyl group Chemical group 0.000 claims 1
MNRSVDHPRAZFQV-NRFANRHFSA-N tert-butyl n-[(2r)-2-(6-acetamidopyridin-3-yl)-2-hydroxyethyl]-n-[2-[4-[2-(methylamino)-2-oxoethyl]phenoxy]ethyl]carbamate Chemical compound C1=CC(CC(=O)NC)=CC=C1OCCN(C(=O)OC(C)(C)C)C[C@H](O)C1=CC=C(NC(C)=O)N=C1 MNRSVDHPRAZFQV-NRFANRHFSA-N 0.000 claims 1
239000000808 adrenergic beta-agonist Substances 0.000 abstract description 10
239000000543 intermediate Substances 0.000 abstract description 5
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 39
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
239000002585 base Substances 0.000 description 29
239000000243 solution Substances 0.000 description 27
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
239000000047 product Substances 0.000 description 24
229940093499 ethyl acetate Drugs 0.000 description 22
235000019439 ethyl acetate Nutrition 0.000 description 22
239000007787 solid Substances 0.000 description 22
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
238000005160 1H NMR spectroscopy Methods 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
239000003153 chemical reaction reagent Substances 0.000 description 13
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
239000002253 acid Substances 0.000 description 11
238000003756 stirring Methods 0.000 description 11
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
239000000758 substrate Substances 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
229940099408 Oxidizing agent Drugs 0.000 description 8
239000010410 layer Substances 0.000 description 8
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
239000013078 crystal Substances 0.000 description 7
150000002924 oxiranes Chemical class 0.000 description 7
150000003254 radicals Chemical class 0.000 description 7
238000011282 treatment Methods 0.000 description 7
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
102000004877 Insulin Human genes 0.000 description 6
108090001061 Insulin Proteins 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
102000012740 beta Adrenergic Receptors Human genes 0.000 description 6
108010079452 beta Adrenergic Receptors Proteins 0.000 description 6
239000012267 brine Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
229940125396 insulin Drugs 0.000 description 6
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
239000000725 suspension Substances 0.000 description 6
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
230000004913 activation Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
LJOQGZACKSYWCH-UHFFFAOYSA-N dihydro quinine Natural products C1=C(OC)C=C2C(C(O)C3CC4CCN3CC4CC)=CC=NC2=C1 LJOQGZACKSYWCH-UHFFFAOYSA-N 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
239000002002 slurry Substances 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
239000005977 Ethylene Substances 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
150000001336 alkenes Chemical class 0.000 description 4
150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 4
201000010099 disease Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
235000011167 hydrochloric acid Nutrition 0.000 description 4
229960000443 hydrochloric acid Drugs 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
229910052763 palladium Inorganic materials 0.000 description 4
239000002798 polar solvent Substances 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000002194 synthesizing effect Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
239000008096 xylene Substances 0.000 description 4
WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
101000924984 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) 3-dehydroquinate dehydratase Proteins 0.000 description 3
WTMGVUKQTIVZTJ-HNNXBMFYSA-N [(2r)-2-(6-acetamidopyridin-3-yl)-2-hydroxyethyl] 4-methylbenzenesulfonate Chemical compound C1=NC(NC(=O)C)=CC=C1[C@@H](O)COS(=O)(=O)C1=CC=C(C)C=C1 WTMGVUKQTIVZTJ-HNNXBMFYSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
TWKVUTXHANJYGH-UHFFFAOYSA-L allyl palladium chloride Chemical class Cl[Pd]CC=C.Cl[Pd]CC=C TWKVUTXHANJYGH-UHFFFAOYSA-L 0.000 description 3
239000000883 anti-obesity agent Substances 0.000 description 3
229940125710 antiobesity agent Drugs 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
229950005499 carbon tetrachloride Drugs 0.000 description 3
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000002140 halogenating effect Effects 0.000 description 3
LJOQGZACKSYWCH-WZBLMQSHSA-N hydroquinine Chemical compound C1=C(OC)C=C2C([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-WZBLMQSHSA-N 0.000 description 3
229960004251 hydroquinine Drugs 0.000 description 3
ZMFMQXXDCVDWFI-UHFFFAOYSA-N n-(5-ethenylpyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC=C(C=C)C=N1 ZMFMQXXDCVDWFI-UHFFFAOYSA-N 0.000 description 3
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
235000010265 sodium sulphite Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 3
UKSZBOKPHAQOMP-HIBFLRMTSA-N (1z,4e)-1,5-diphenylpenta-1,4-dien-3-one;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1/C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-HIBFLRMTSA-N 0.000 description 2
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 2
JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 2
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
208000021017 Weight Gain Diseases 0.000 description 2
210000000577 adipose tissue Anatomy 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000006256 asymmetric dihydroxylation reaction Methods 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000007547 defect Effects 0.000 description 2
YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
238000005906 dihydroxylation reaction Methods 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002024 ethyl acetate extract Substances 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
XYBRWUNZRUBCGY-UHFFFAOYSA-N methyl n-(5-bromopyridin-2-yl)carbamate Chemical compound COC(=O)NC1=CC=C(Br)C=N1 XYBRWUNZRUBCGY-UHFFFAOYSA-N 0.000 description 2
LHJMFFKVXROWOC-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=C(Br)C=N1 LHJMFFKVXROWOC-UHFFFAOYSA-N 0.000 description 2
MJFCOXATGBYERZ-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC=C(Br)C=N1 MJFCOXATGBYERZ-UHFFFAOYSA-N 0.000 description 2
DUTJLVHVDAXHDN-UHFFFAOYSA-N n-[5-(1,2-dihydroxyethyl)pyridin-2-yl]acetamide Chemical compound CC(=O)NC1=CC=C(C(O)CO)C=N1 DUTJLVHVDAXHDN-UHFFFAOYSA-N 0.000 description 2
WAXONIBXUBSLKF-QMMMGPOBSA-N n-[5-[(1r)-2-chloro-1-hydroxyethyl]pyridin-2-yl]acetamide Chemical compound CC(=O)NC1=CC=C([C@@H](O)CCl)C=N1 WAXONIBXUBSLKF-QMMMGPOBSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000012285 osmium tetroxide Substances 0.000 description 2
229910000489 osmium tetroxide Inorganic materials 0.000 description 2
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229910000073 phosphorus hydride Inorganic materials 0.000 description 2
239000003880 polar aprotic solvent Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000004648 relaxation of smooth muscle Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000006884 silylation reaction Methods 0.000 description 2
229960001407 sodium bicarbonate Drugs 0.000 description 2
235000011121 sodium hydroxide Nutrition 0.000 description 2
229940083608 sodium hydroxide Drugs 0.000 description 2
CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
230000007704 transition Effects 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
DVYKQANXDBJSGF-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-n-methylacetamide Chemical compound CNC(=O)CC1=CC=C(O)C=C1 DVYKQANXDBJSGF-UHFFFAOYSA-N 0.000 description 1
RJHOBUHNUIBRHM-UHFFFAOYSA-N 2-[4-(2-aminoethoxy)phenyl]acetamide Chemical compound NCCOC1=CC=C(CC(N)=O)C=C1 RJHOBUHNUIBRHM-UHFFFAOYSA-N 0.000 description 1
BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 description 1
BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
101100240526 Caenorhabditis elegans nhr-20 gene Proteins 0.000 description 1
101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
LJOQGZACKSYWCH-AFHBHXEDSA-N Hydroquinidine Natural products C1=C(OC)C=C2C([C@@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-AFHBHXEDSA-N 0.000 description 1
241000694408 Isomeris Species 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
208000011623 Obstructive Lung disease Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
BEUYHSHHOBJIAB-AWEZNQCLSA-N [(2r)-2-(6-acetamidopyridin-3-yl)-2-hydroxyethyl] 4-nitrobenzenesulfonate Chemical compound C1=NC(NC(=O)C)=CC=C1[C@@H](O)COS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 BEUYHSHHOBJIAB-AWEZNQCLSA-N 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000000746 allylic group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
SAGINAGERRNGGV-UHFFFAOYSA-N benzyl n-(2-hydroxyethyl)carbamate Chemical compound OCCNC(=O)OCC1=CC=CC=C1 SAGINAGERRNGGV-UHFFFAOYSA-N 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000025938 carbohydrate utilization Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000002027 dichloromethane extract Substances 0.000 description 1
SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
SVABQOITNJTVNJ-UHFFFAOYSA-N diphenyl-2-pyridylphosphine Chemical compound C1=CC=CC=C1P(C=1N=CC=CC=1)C1=CC=CC=C1 SVABQOITNJTVNJ-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
239000004210 ether based solvent Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229960000811 hydroquinidine Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
XGDZEDRBLVIUMX-UHFFFAOYSA-N methyl 2-(4-hydroxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C=C1 XGDZEDRBLVIUMX-UHFFFAOYSA-N 0.000 description 1
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
FKLJENIOOVXDPY-UHFFFAOYSA-N methyl n-(5-ethenylpyridin-2-yl)carbamate Chemical compound COC(=O)NC1=CC=C(C=C)C=N1 FKLJENIOOVXDPY-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
ZFIULJUUXQPOQO-UHFFFAOYSA-N n-(3-ethenylpyridin-2-yl)acetamide Chemical compound CC(=O)NC1=NC=CC=C1C=C ZFIULJUUXQPOQO-UHFFFAOYSA-N 0.000 description 1
DUSUDDSKKLCVMN-UHFFFAOYSA-N n-(5-ethenylpyridin-2-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=C(C=C)C=N1 DUSUDDSKKLCVMN-UHFFFAOYSA-N 0.000 description 1
DUTJLVHVDAXHDN-QMMMGPOBSA-N n-[5-[(1r)-1,2-dihydroxyethyl]pyridin-2-yl]acetamide Chemical compound CC(=O)NC1=CC=C([C@@H](O)CO)C=N1 DUTJLVHVDAXHDN-QMMMGPOBSA-N 0.000 description 1
LWFWUJCJKPUZLV-UHFFFAOYSA-N n-trimethylsilylacetamide Chemical compound CC(=O)N[Si](C)(C)C LWFWUJCJKPUZLV-UHFFFAOYSA-N 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
150000002940 palladium Chemical class 0.000 description 1
125000000914 phenoxymethylpenicillanyl group Chemical group CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(COC2=CC=CC=C2)=O)=O)C 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
229960005235 piperonyl butoxide Drugs 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
VKJKEPKFPUWCAS-UHFFFAOYSA-M potassium chlorate Chemical compound [K+].[O-]Cl(=O)=O VKJKEPKFPUWCAS-UHFFFAOYSA-M 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
208000017497 prostate disease Diseases 0.000 description 1
238000010926 purge Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
UAIHPMFLFVHDIN-UHFFFAOYSA-K trichloroosmium Chemical compound Cl[Os](Cl)Cl UAIHPMFLFVHDIN-UHFFFAOYSA-K 0.000 description 1
DCXPBOFGQPCWJY-UHFFFAOYSA-N trisodium;iron(3+);hexacyanide Chemical compound [Na+].[Na+].[Na+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCXPBOFGQPCWJY-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pyridine Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

OA9900096A 1996-11-14 1999-05-07 Process for substituted pyridines OA11044A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3088096P	1996-11-14	1996-11-14

Publications (1)

Publication Number	Publication Date
OA11044A true OA11044A (en)	2002-02-20

Family

ID=21856496

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900096A OA11044A (en)	1996-11-14	1999-05-07	Process for substituted pyridines

Country Status (32)

Country	Link
US (1)	US6291489B1 (fr)
EP (1)	EP0938476B1 (fr)
JP (1)	JP3510635B2 (fr)
KR (1)	KR20000053314A (fr)
CN (1)	CN1237160A (fr)
AP (1)	AP805A (fr)
AR (1)	AR010584A1 (fr)
AT (1)	ATE319687T1 (fr)
AU (1)	AU4634697A (fr)
BG (1)	BG103393A (fr)
BR (1)	BR9712951A (fr)
CA (1)	CA2270386C (fr)
CO (1)	CO4930261A1 (fr)
DE (1)	DE69735433D1 (fr)
EA (1)	EA199900375A1 (fr)
GT (1)	GT199700118A (fr)
HR (1)	HRP970612A2 (fr)
ID (1)	ID18898A (fr)
IL (1)	IL129688A0 (fr)
IS (1)	IS5029A (fr)
MA (1)	MA24401A1 (fr)
MY (1)	MY132507A (fr)
NO (1)	NO992296D0 (fr)
OA (1)	OA11044A (fr)
PA (1)	PA8441401A1 (fr)
PE (1)	PE10299A1 (fr)
TN (1)	TNSN97172A1 (fr)
TR (1)	TR199901063T2 (fr)
UY (1)	UY24774A1 (fr)
WO (1)	WO1998021184A1 (fr)
YU (1)	YU22099A (fr)
ZA (1)	ZA9710186B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ID26299A (id) *	1998-04-08	2000-12-14	Novartis Ag	Herbisida baru
US6090942A (en) *	1998-10-15	2000-07-18	Pfizer Inc.	Process and intermediates for a β3 -adrenergic receptor agonist
CA2362070A1 (fr) *	1999-02-16	2000-08-24	Masaru Mitsuda	Derives d'acetylpyridine substituee et procede de preparation d'intermediaires pour agoniste du recepteur adrenergique .beta.3 optiquement actif, faisant appel a ces derives
US6455734B1 (en) *	2000-08-09	2002-09-24	Magnesium Diagnostics, Inc.	Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
DE60015036T2 (de) *	1999-07-23	2006-03-02	Pfizer Products Inc., Groton	Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
US20040265991A1 (en) *	2001-10-17	2004-12-30	Naoaki Taoka	Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives
WO2003072573A1 (fr) *	2002-02-27	2003-09-04	Pfizer Products Inc.	Formes cristallines de (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en)	2002-02-27	2005-03-08	Pfizer Inc.	β3 adrenergic receptor agonists
EP1478625A1 (fr)	2002-02-27	2004-11-24	Pfizer Products Inc.	Procedes et intermediaires utiles dans la preparation d'agonistes du recepteur beta-3-adrenergique
EP1424079A1 (fr) *	2002-11-27	2004-06-02	Boehringer Ingelheim International GmbH	Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
ATE406363T1 (de)	2003-05-09	2008-09-15	Hoffmann La Roche	Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
GB2431927B (en)	2005-11-04	2010-03-17	Amira Pharmaceuticals Inc	5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en)	2005-11-04	2013-03-19	Panmira Pharmaceuticals, Llc	5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en)	2005-11-04	2011-07-12	Amira Pharmaceuticals, Inc.	5-lipdxygenase-activating protein (FLAP) inhibitors
JP5791500B2 (ja)	2008-05-23	2015-10-07	パンミラファーマシューティカルズ，エルエルシー．	５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en)	2008-10-01	2013-10-01	Panmira Pharmaceuticals, Llc	5-lipoxygenase-activating protein (FLAP) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4358455A (en)	1980-12-23	1982-11-09	Merck & Co., Inc.	Aralkylamindethanol heterocyclic compounds
US5019578A (en)	1987-11-27	1991-05-28	Merck & Co., Inc.	β-adrenergic agonists
ATE154935T1 (de)	1993-06-14	1997-07-15	Pfizer	Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
IL113410A (en)	1994-04-26	1999-11-30	Merck & Co Inc	Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
WO1996035670A1 (fr) *	1995-05-10	1996-11-14	Pfizer Inc.	AGONISTES DU RECEPTEUR β-ADRENERGIQUE
JPH11504649A (ja) *	1995-05-10	1999-04-27	ファイザー・インコーポレーテッド	β−アドレナリン作働性アゴニスト

1997
- 1997-11-03 WO PCT/IB1997/001367 patent/WO1998021184A1/fr not_active Ceased
- 1997-11-03 US US09/297,694 patent/US6291489B1/en not_active Expired - Fee Related
- 1997-11-03 AT AT97945047T patent/ATE319687T1/de not_active IP Right Cessation
- 1997-11-03 EA EA199900375A patent/EA199900375A1/ru unknown
- 1997-11-03 BR BR9712951-8A patent/BR9712951A/pt not_active Application Discontinuation
- 1997-11-03 IL IL12968897A patent/IL129688A0/xx unknown
- 1997-11-03 TR TR1999/01063T patent/TR199901063T2/xx unknown
- 1997-11-03 CA CA002270386A patent/CA2270386C/fr not_active Expired - Fee Related
- 1997-11-03 YU YU22099A patent/YU22099A/sh unknown
- 1997-11-03 KR KR1019990704312A patent/KR20000053314A/ko not_active Abandoned
- 1997-11-03 EP EP97945047A patent/EP0938476B1/fr not_active Expired - Lifetime
- 1997-11-03 CN CN97199663A patent/CN1237160A/zh active Pending
- 1997-11-03 DE DE69735433T patent/DE69735433D1/de not_active Expired - Lifetime
- 1997-11-03 JP JP52233298A patent/JP3510635B2/ja not_active Expired - Fee Related
- 1997-11-03 AU AU46346/97A patent/AU4634697A/en not_active Abandoned
- 1997-11-11 GT GT199700118A patent/GT199700118A/es unknown
- 1997-11-11 PE PE1997001004A patent/PE10299A1/es not_active Application Discontinuation
- 1997-11-11 MA MA24864A patent/MA24401A1/fr unknown
- 1997-11-12 PA PA19978441401A patent/PA8441401A1/es unknown
- 1997-11-12 UY UY24774A patent/UY24774A1/es unknown
- 1997-11-12 AR ARP970105279A patent/AR010584A1/es not_active Application Discontinuation
- 1997-11-12 ZA ZA9710186A patent/ZA9710186B/xx unknown
- 1997-11-12 TN TNTNSN97172A patent/TNSN97172A1/fr unknown
- 1997-11-12 MY MYPI97005396A patent/MY132507A/en unknown
- 1997-11-13 HR HR60/030,880A patent/HRP970612A2/hr not_active Application Discontinuation
- 1997-11-13 AP APAP/P/1997/001147A patent/AP805A/en active
- 1997-11-13 ID IDP973662A patent/ID18898A/id unknown
- 1997-11-13 CO CO97066763A patent/CO4930261A1/es unknown
1999
- 1999-04-16 IS IS5029A patent/IS5029A/is unknown
- 1999-05-07 OA OA9900096A patent/OA11044A/en unknown
- 1999-05-11 BG BG103393A patent/BG103393A/xx unknown
- 1999-05-12 NO NO992296A patent/NO992296D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1998021184A1 (fr)	1998-05-22
ATE319687T1 (de)	2006-03-15
PE10299A1 (es)	1999-02-10
AP805A (en)	2000-01-28
ID18898A (id)	1998-05-20
AU4634697A (en)	1998-06-03
EP0938476A1 (fr)	1999-09-01
EA199900375A1 (ru)	1999-12-29
EP0938476B1 (fr)	2006-03-08
BR9712951A (pt)	1999-12-07
GT199700118A (es)	1999-05-05
AR010584A1 (es)	2000-06-28
US6291489B1 (en)	2001-09-18
CO4930261A1 (es)	2000-06-27
IL129688A0 (en)	2000-02-29
UY24774A1 (es)	1998-05-05
TR199901063T2 (xx)	1999-08-23
CN1237160A (zh)	1999-12-01
CA2270386C (fr)	2004-08-03
DE69735433D1 (de)	2006-05-04
JP3510635B2 (ja)	2004-03-29
AP9701147A0 (en)	1998-01-31
TNSN97172A1 (fr)	2005-03-15
MY132507A (en)	2007-10-31
ZA9710186B (en)	1999-05-12
HRP970612A2 (en)	1998-08-31
NO992296L (no)	1999-05-12
BG103393A (en)	2000-07-31
IS5029A (is)	1999-04-16
KR20000053314A (ko)	2000-08-25
MA24401A1 (fr)	1998-07-01
CA2270386A1 (fr)	1998-05-22
JP2000504347A (ja)	2000-04-11
NO992296D0 (no)	1999-05-12
YU22099A (sh)	2001-09-28
PA8441401A1 (es)	2000-05-24

Publication	Publication Date	Title
JP7580136B2 (ja)	2024-11-11	Ｊａｋ阻害剤化合物及びその使用
US6031105A (en)	2000-02-29	Substituted pyridines
US6291489B1 (en)	2001-09-18	Process for substituted pyridines
AU2022259328A1 (en)	2023-11-09	Bicyclic substituted aromatic carboxylic acid compounds
TWI651305B (zh)	2019-02-21	製備ｐｄｅ４抑制劑之方法
JP2023553173A (ja)	2023-12-20	甲状腺ホルモン受容体β選択のアゴニスト化合物、その医薬組成物および用途
JPH0283375A (ja)	1990-03-23	２−置換ピペラジニル−２−（１，２−ベンズイソキサゾール−３−イル）酢酸誘導体
RU2162470C2 (ru)	2001-01-27	2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
EP0566593A1 (fr)	1993-10-27	Derives de n-hydroxyuree utilises comme agents anti-allergiques et anti-inflammatoires
WO2022007772A1 (fr)	2022-01-13	Dérivé de benzimidazole substitué et son utilisation
JP3213576B2 (ja)	2001-10-02	置換ピリジン
US6124457A (en)	2000-09-26	Process and intermediates for a β3 -adrenergic receptor agonist
US6008361A (en)	1999-12-28	Substituted pyridines
AU2004254226C1 (en)	2009-07-02	2,4-bis(trifluoroethoxy)pyridine compound and medicine containing the same
JPS6350343B2 (fr)	1988-10-07
MXPA99004459A (en)	2000-02-02	Process for substituted pyridines
CZ169499A3 (cs)	2000-05-17	Způsoby výroby substituovaných pyridinů
JPH037279A (ja)	1991-01-14	２―チオピランカルボチオアミド誘導体
CN117321053A (zh)	2023-12-29	P300抑制剂及其在医药上的应用
AU3334801A (en)	2001-12-13	Process for preparing substituted pyridines
WO2019184772A1 (fr)	2019-10-03	Composé de type gibbérelline, son procédé de préparation, sa composition pharmaceutique, ses applications et son intermédiaire
JPS5910358B2 (ja)	1984-03-08	新規エルゴリン誘導体
WO2012115177A1 (fr)	2012-08-30	Dérivé de n-[(biaryloxy)alkylcarbonyle]sulfonamide
PT1661890E (pt)	2011-04-04	Composto de activação dos ppar e composição farmacêutica contendo o mesmo